Oxaliplatin/Norcantharidin Prodrug Co‐Loaded Nanoparticles: Synergistic DNA‐Repair Blockade Plus PD‐L1 Downregulation for Inhibit Tumor Growth and Metastasis
Advanced Healthcare Materials · 2026-05 · 15 (17)
DOI: 10.1002/adhm.202505173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 20.02.2026. Verfasst von Peng-Wei Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Henan Key Laboratory of Natural Medicine Innovation and Transformation, Henan University, China. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Nanoparticles, Oxaliplatin, Prodrugs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Henan Province, Youth Cross Fund Key Project of Henan University.
Abstract (Originalsprache)
The combination of phototherapy with oxaliplatin (OXA) represents a potent strategy for triggering immunogenic cell death (ICD) and elicit robust antitumor immunity. In this study, we construct IROTD nanoparticles (IROTD NPs) through self‐assembly of a norcantharidin (NCTD)‐OXA‐conjugated polymer (P2) and the near‐infrared (NIR) photosensitizer DTIR780. Under 808 nm laser irradiation, IROTD NPs generate heat and reactive oxygen species (ROS) while release OXA and NCTD, result in severe DNA damage and potent induction of ICD within tumor cells. Concurrently, NCTD inhibits DNA repair mechanisms and down‐regulates PD‐L1expression, thereby increase the infiltration of cytotoxic T‐cell and amplify systemic antitumor immunity. Leverage the enhanced permeability and retention (EPR) effect, IROTD NPs efficiently accumulate at tumor sites, result in remarkable inhibition of tumor growth and recruitment of CD4 + and CD8 + T lymphocytes, which collectively contribute to the activation of a systemic antitumor immunity. In a bilateral tumor model, IROTD NPs effectively inhibit both primary and distant tumor growth. Overall, this work presents a rationally designed combinatorial nanoplatform that effectively ignites systemic immune response, thus establish a prospective chemo‐immunotherapeutic stratagem for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Key Laboratory of Natural Medicine Innovation and Transformation, Henan University, China.
- State Key Laboratory of Antiviral Drugs, Henan University, Kaifeng, China.
- The Zhongzhou Laboratory for Integrative Biology, Henan University, Kaifeng, China.
ORCID-Profile: Mei-Xia Zhao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Henan Province
- Youth Cross Fund Key Project of Henan University
Zitieren
APA
Chen, P. W., Zhang, Y. M., Li, L. S., Liu, B. B., Sun, H. L., Chen, L., Yang, X., & Zhao, M. X. (2026). Oxaliplatin/Norcantharidin Prodrug Co‐Loaded Nanoparticles: Synergistic DNA‐Repair Blockade Plus PD‐L1 Downregulation for Inhibit Tumor Growth and Metastasis. Advanced Healthcare Materials, 15(17). https://doi.org/10.1002/adhm.202505173
Vancouver
Chen PW, Zhang YM, Li LS, Liu BB, Sun HL, Chen L, et al. Oxaliplatin/Norcantharidin Prodrug Co‐Loaded Nanoparticles: Synergistic DNA‐Repair Blockade Plus PD‐L1 Downregulation for Inhibit Tumor Growth and Metastasis. Advanced Healthcare Materials. 2026;15(17). doi:10.1002/adhm.202505173
BibTeX
@article{Chen2026,
author = {Chen, Peng-Wei and Zhang, Yu-Meng and Li, Lin-Song and Liu, Bang-Bang and Sun, Han-Lu and Chen, Liping and Yang, Xiaojing and Zhao, Mei-Xia},
title = {Oxaliplatin/Norcantharidin Prodrug Co‐Loaded Nanoparticles: Synergistic DNA‐Repair Blockade Plus PD‐L1 Downregulation for Inhibit Tumor Growth and Metastasis},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {17},
doi = {10.1002/adhm.202505173}
}
EUVIMED